TSHA
Taysha Gene Therapies, Inc.
Taysha Gene Therapies, Inc. (TSHA) has 10 SEC Form 4 filings (14 transaction rows) in the rolling window, disclosed by 3 distinct insiders. Most recent filing: Jul 10, 2026.
The most active filer is President and Head of R&D Nagendran Sukumar with 4 filings. Insiders have net sold $4.0M over the trailing 6 months.
- Industry:Biotechnology
- CEO:Sean Nolan
- Employees:99
- HQ:Dallas, TX, US
- IPO:2020-09-24
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$4.0M
reported sales (SEC code S)
Unique Insiders
3
in the rolling window
Market Cap
$1.9B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| President and Head of R&D | Sale | 200,000 | $1.2M | Jul 10 | SEC ↗ | |
| President and Head of R&D | Sale | 200,000 | $892K | Apr 13 | SEC ↗ | |
| CHIEF FINANCIAL OFFICER | Sale | 1,655 | $7K | Feb 6 | SEC ↗ | |
Nagendran SukumarFirst filing | President and Head of R&D | Sale | 89,132 | $423K | Jan 27 | SEC ↗ |
Nagendran SukumarFirst filing | President and Head of R&D | Sale | 26,918 | $124K | Jan 27 | SEC ↗ |
Alam KamranFirst filing | CHIEF FINANCIAL OFFICER | Sale | 78,968 | $375K | Jan 27 | SEC ↗ |
Alam KamranFirst filing | CHIEF FINANCIAL OFFICER | Sale | 23,849 | $110K | Jan 27 | SEC ↗ |
Nolan Sean P.First filing | Chief Executive Officer | Sale | 136,789 | $650K | Jan 27 | SEC ↗ |
Nolan Sean P.First filing | Chief Executive Officer | Sale | 41,312 | $190K | Jan 27 | SEC ↗ |
Related companies
Taysha Gene Therapies, Inc. is in the Healthcare sector.